Borosil Scientific Limited — PPTs, 12-11-2025: Investor Presentation

Borosil Scientific's Q2FY26 consolidated sales rose 3.8% YoY to ₹106.9 Cr, while H1FY26 sales dipped 2.3% to ₹202.9 Cr. Profit after tax (PAT) saw a significant decline, with H1FY26 reporting a loss of ₹1.4 Cr. This was primarily due to a one-time VRS expense of ₹6.61 Cr and temporary operational challenges in Pharma Packaging, alongside delayed orders in Process Systems. Positively, Lab Consumables grew 15.3% and Lab Equipment 25.5% YoY in Q2.

The company's strategy focuses on 'Make in India', leveraging its trusted brand, continuous new product development, and expanding exports to over 90 countries. Recent highlights include achieving ISI Glassware certification and commissioning a 450 kW solar project. Management projects a 12-14% revenue CAGR and improved EBITDA margins, driven by high-margin segments and strong order bookings for H2FY26, signaling a positive future outlook.